Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.
about
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trialsAgents and strategies in development for improved management of herpes simplex virus infection and disease.Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants.Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections.A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infectionsSouth Africa's experience of the closure of the cellulose sulphate microbicide trialHSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target.Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safetySusceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safetyCandidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action.Herpes simplex virus-induced epithelial damage and susceptibility to human immunodeficiency virus type 1 infection in human cervical organ culture.PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trialThe cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India.Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections.Feasibility of Repurposing the Polyanionic Microbicide, PPCM, for Prophylaxis against HIV Transmission during ART.Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies.Non-specific microbicide product development: then and nowNovel vaginal microflora colonization model providing new insight into microbicide mechanism of action.Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus.Cutaneous infections and infestations: new therapiesDynasore disrupts trafficking of herpes simplex virus proteinssiRNA-based topical microbicides targeting sexually transmitted infections.Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infectionsPotential role of tenofovir vaginal gel for reduction of risk of herpes simplex virus in femalesProteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implicationsEpigallocatechin gallate inactivates clinical isolates of herpes simplex virus.The Cholestanol-Conjugated Sulfated Oligosaccharide PG545 Disrupts the Lipid Envelope of Herpes Simplex Virus Particles.Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transferImpact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract.Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine modelGriffithsin protects mice from genital herpes by preventing cell-to-cell spreadExploiting herpes simplex virus entry for novel therapeutics.Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study.The differential binding and activity of PRO 2000 against diverse HIV-1 envelopes.Novel approaches in fighting herpes simplex virus infectionsPolyanionic drugs and viral oncogenesis: a novel approach to control infection, tumor-associated inflammation and angiogenesis.Heparosan-derived heparan sulfate/heparin-like compounds: one kind of potential therapeutic agents.Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.
P2860
Q28749211-E7B0FEA5-8F64-4F54-9CC6-645B24A03ADAQ30350341-567F5425-E626-4F4B-BBE6-E1CADCB62150Q30356032-8A279DE8-0A8C-46D2-A41A-437BF9AFE7E7Q30359545-BC069800-1770-40AE-B564-543B94C256AAQ30369008-BB4BF069-FC04-4428-958F-DC7088C7AAFCQ33293586-305AD883-05F3-47A0-A5AE-D39686FCCEE5Q33646802-0964971A-327A-4E22-A298-799D5F026732Q33880947-68881D21-A0D1-463F-A84F-54811A5583F0Q33889911-EE882154-0B34-4F44-A7FB-4C3988CB66F3Q33935475-84416604-5B02-4510-BD37-18A6F0C47780Q33983315-28321D94-0791-426B-9460-15035C414F8DQ34138687-DB2DC6BF-441F-452C-ADA2-10AFDC5166E5Q34142834-888DDB92-1097-41B1-8F63-73D61680740AQ34538247-53391C56-ACCC-4343-B15F-337C656DC612Q34680240-62108E1C-9E9F-40AE-B645-F3DE42566E5DQ34998344-E0F0F7A0-5166-47B3-B8DA-D5F75BAA5C44Q35156674-A9FFDB55-BA2F-4A7A-BCE7-42CF288F2449Q35256845-0BC242C4-8D5E-4AA3-AF22-290B8D85CEBCQ35345283-2A99365D-44ED-493E-8C92-5E9F8FDE7151Q35458113-0A7F08D1-816D-4D38-9618-B9D304A8A06EQ35598372-75CC0495-3A54-40AD-B7EC-0CED3AFDEC54Q35628618-25D0E7F5-4450-4B91-84D9-EEC2C6CF558CQ35745437-5C11B8E9-D233-44D1-B3A0-78EECE50AF03Q35766254-D8F4FDA2-D180-460A-A133-F62835082C8DQ35914529-3890D25C-9402-445B-9B36-4B014D4434B5Q36173112-0D7CA89A-C4E3-4FCA-A23F-C4FAAF6DA890Q36253322-AF7356B0-E6E8-4E7C-A28F-77ED0CB450EDQ36482815-4A792456-36A4-449C-A2F6-E57BDA20CF99Q36571976-5EC9C12E-DEED-4AFA-AF02-88719FCA3B01Q36593842-27648796-B094-4C68-837B-B616A4B9E223Q36640429-3841E99F-E7C1-4CA6-9623-E1AF527EC930Q36748039-C2C66323-455D-4B02-BA26-9C9FBD2B4C27Q36827173-0E119220-188B-4925-81B3-E5B54F59EC6AQ37030702-03758563-5C0C-44D5-A3DC-1AF914FB4455Q37107494-CB79D757-0A36-4824-8035-00E513B06DE0Q37283747-C1765431-3475-4CD9-871F-68C8EC4DAAD5Q37316071-2B621005-D85F-412F-B6EE-BB6E580942A2Q37323266-28F5F70E-BCFA-47E3-8891-4AA00A278029Q38001955-966C34F6-3160-462B-9B2A-E64D40166FC9Q38248209-9B1A5177-F8B2-4E58-B91A-1D21C49B0AA8
P2860
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Candidate topical microbicides ...... entry and cell-to-cell spread.
@ast
Candidate topical microbicides ...... entry and cell-to-cell spread.
@en
Candidate topical microbicides ...... entry and cell-to-cell spread.
@nl
type
label
Candidate topical microbicides ...... entry and cell-to-cell spread.
@ast
Candidate topical microbicides ...... entry and cell-to-cell spread.
@en
Candidate topical microbicides ...... entry and cell-to-cell spread.
@nl
prefLabel
Candidate topical microbicides ...... entry and cell-to-cell spread.
@ast
Candidate topical microbicides ...... entry and cell-to-cell spread.
@en
Candidate topical microbicides ...... entry and cell-to-cell spread.
@nl
P2093
P2860
P1476
Candidate topical microbicides ...... entry and cell-to-cell spread.
@en
P2093
Albert T Profy
Betsy C Herold
Donald P Waller
Gary A Jarvis
Jin-Hua Li
Kathleen Hogarty
Lourens J D Zaneveld
Marla J Keller
Mary E Klotman
P2860
P304
P356
10.1128/AAC.48.6.2025-2036.2004
P407
P577
2004-06-01T00:00:00Z